Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 134

Sort by

Sort Order Select

Journal Articles

Therapeutic preclinical study on the synergy between CD73 inhibitors and selinexor for managing multiple myeloma

Chun-Li Zhang, Qiuxia Wei, Nigmat Rahim, Gang Bian, Chaoling Wu, Jing Wang, Ping Yang, Jiahui Hua, Mingxia Zhu, Yingtong Chen, Yan Liu, Shuang Gao, Bing Hou, Weilong Zhang, Hongmei Jing

Blood (2025) 146 (Supplement 1): 7455.

https://doi.org/10.1182/blood-2025-7455

Published: 2025

Journal Articles

Trial in progress: A phase II, multicentre study to evaluate the efficacy and safety of birelentinib (DZD8586) combination therapy in diffuse large B-cell lymphoma (TAI-SHAN12)

Huiqiang Huang, Wenyu Li, Liqun Zou, Yajun Li, Fang Zhu, Keshu Zhou, Yun Liang, Meifang Zheng, Zengjun Li, Hongmei Jing, Wei Yang, Pengcheng He, Kaiyang Ding, Yuhua Li, Mengling Zhong, Ziyi Liu, Liping Su

Blood (2025) 146 (Supplement 1): 8238.

https://doi.org/10.1182/blood-2025-8238

Published: 2025

Journal Articles

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Blood (2025) 146 (Supplement 1): 475.

https://doi.org/10.1182/blood-2025-475

Published: 2025

Journal Articles

Analysis of factors associated with clinical response in glofitamab's treatment of relapsed or refractory (R/R) large B-cell lymphoma

Lan Luo, Yaxin Zheng, Ping Yang, Xu Zhang, Fei Dong, Jijun Wang, Hongmei Jing

Blood (2025) 146 (Supplement 1): 7262.

https://doi.org/10.1182/blood-2025-7262

Published: 2025

Journal Articles

Efficacy and safety of zanubrutinib combined with reduced-dose bendamustine and Rituximab for eldly Mantle Cell Lymphoma: A retrospective analysis

Ping Yang, Shuozi Liu, Chuanyuan Li, Lan Luo, Weilong Zhang, Jing Wang, Hongmei Jing

Blood (2025) 146 (Supplement 1): 7097.

https://doi.org/10.1182/blood-2025-7097

Published: 2025

Journal Articles

Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study

Blood (2025) 146 (Supplement 1): 5830.

https://doi.org/10.1182/blood-2025-5830

Published: 2025

Journal Articles

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

Blood (2025) 146 (Supplement 1): 5819.

https://doi.org/10.1182/blood-2025-5819

Published: 2025

Journal Articles

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

Blood (2025) 146 (Supplement 1): 5818.

https://doi.org/10.1182/blood-2025-5818

Published: 2025

Journal Articles

Prognostic and therapeutic implications of the immune landscape in Mantle Cell Lymphoma

Changjian Yan, Chaoling Wu, Ping Yang, Xiaoyu Hao, Jie Chen, Jing Wang, Mingxia Zhu, Yan Liu, Hongmei Jing, Weilong Zhang

Blood (2025) 146 (Supplement 1): 1821.

https://doi.org/10.1182/blood-2025-1821

Published: 2025

Journal Articles

JS203, a CD20×CD3 bispecific antibody, demonstrated promising anti-cancer activity in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL): Updated results from a phase I study

Blood (2025) 146 (Supplement 1): 1957.

https://doi.org/10.1182/blood-2025-1957

Published: 2025

Journal Articles

Mitoxantrone hydrochloride liposome, gemcitabine, vinorelbine with or without anti-CD20 antibody (GVM±CD20) in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: A prospective, multicenter, Phase Ⅱ study

Blood (2025) 146 (Supplement 1): 1919.

https://doi.org/10.1182/blood-2025-1919

Published: 2025

Journal Articles

Preliminary results from a phase 1/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma

Fei Li, Stephen Opat, Dengju Li, Keshu Zhou, Peng Liu, Wei Yang, Chan Cheah, Tingyu Wang, Yu Yang, Caixia Li, Hongmei Jing, Henry Ngu, Lipeng Chen, Ting Deng, Fangjie Xie, Naisargee Shah, Zhao Xu, Richard Delarue, Jianyong Li

Blood (2025) 146 (Supplement 1): 1910.

https://doi.org/10.1182/blood-2025-1910

Published: 2025

Journal Articles

Combination of mitoxantrone hydrochloride liposome with gemcitabine, cisplatin and dexamethasone (MGDP) in patients with relapsed or refractory peripheral T cell lymphoma: A prospective, single-arm, multicenter, Phase I/II study

Chong Wei, Yang Song, Shengyu Zhou, Shuangnian Xu, Hongmei Jing, Hui Liu, Wei Zhang, Dao-Bin Zhou

Blood (2025) 146 (Supplement 1): 5423.

https://doi.org/10.1182/blood-2025-5423

Published: 2025

Journal Articles

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial

Blood (2025) 146 (Supplement 1): 1796.

https://doi.org/10.1182/blood-2025-1796

Published: 2025

Journal Articles

Does intensive consolidation confer a clinical advantage over continued less intensive therapy in elderly patients with Acute Myeloid Leukemia in first remission following azacitidine plus venetoclax induction?

Blood (2025) 146 (Supplement 1): 5162.

https://doi.org/10.1182/blood-2025-5162

Published: 2025

Journal Articles

Safety and effectiveness of brentuximab vedotin in Chinese adult patients with classical Hodgkin's lymphoma: Results from a multicenter, prospective, observational, real-world study

Wei Li, Chuanxu Liu, Wenyang Huang, Ou Bai, Lihong Liu, Zengjun Li, Wei Xu, Wei Zhang, Liping Su, Kaiyang Ding, Luqun Wang, Guohui Cui, Hongmei Jing, Jianli Wang, Ziheng Guo, Weili Zhao, Huilai Zhang

Blood (2025) 146 (Supplement 1): 7135.

https://doi.org/10.1182/blood-2025-7135

Published: 2025

Journal Articles

Phase I study of a CD19-directed CAR-T cell therapy for Relapsed/refractory mantle cell lymphomas(MCL)

Ping Yang, Jinjie Gao, Lan Luo, Weilong Zhang, Jing Wang, Hongmei Jing

Blood (2025) 146 (Supplement 1): 7125.

https://doi.org/10.1182/blood-2025-7125

Published: 2025

Journal Articles

Short-term follow-up results of ultra-low-dose radiotherapy for indolent B-cell lymphoma

Min Li, Ran Peng, Ping Yang, Fang Bao, Jijun Wang, Qihui Li, Hongmei Jing, Hao Wang

Blood (2025) 146 (Supplement 1): 7113.

https://doi.org/10.1182/blood-2025-7113

Published: 2025

Journal Articles

Genomic characterization uncovers molecular subtypes in Mantle Cell Lymphoma

Changjian Yan, Ping Yang, Jie Chen, Chaoling Wu, Xiaoyu Hao, Jing Wang, Mingxia Zhu, Yan Liu, Weilong Zhang, Hongmei Jing

Blood (2025) 146 (Supplement 1): 3590.

https://doi.org/10.1182/blood-2025-3590

Published: 2025

Journal Articles

Heterogeneous TP53 mutation subtypes define prognostic classification in Mantle Cell Lymphoma

Shuozi Liu, Ping Yang, Shaowei Zhou, Weilong Zhang, Jing Wang, Lingli Wang, Chunyuan Li, Yingtong Chen, Wenxin Qi, Hongmei Jing

Blood (2025) 146 (Supplement 1): 3589.

https://doi.org/10.1182/blood-2025-3589

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Therapeutic preclinical study on the synergy between CD73 inhibitors and selinexor for managing multiple myeloma

Trial in progress: A phase II, multicentre study to evaluate the efficacy and safety of birelentinib (DZD8586) combination therapy in diffuse large B-cell lymphoma (TAI-SHAN12)

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Analysis of factors associated with clinical response in glofitamab's treatment of relapsed or refractory (R/R) large B-cell lymphoma

Efficacy and safety of zanubrutinib combined with reduced-dose bendamustine and Rituximab for eldly Mantle Cell Lymphoma: A retrospective analysis

Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

Prognostic and therapeutic implications of the immune landscape in Mantle Cell Lymphoma

JS203, a CD20×CD3 bispecific antibody, demonstrated promising anti-cancer activity in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL): Updated results from a phase I study

Mitoxantrone hydrochloride liposome, gemcitabine, vinorelbine with or without anti-CD20 antibody (GVM±CD20) in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: A prospective, multicenter, Phase Ⅱ study

Preliminary results from a phase 1/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma

Combination of mitoxantrone hydrochloride liposome with gemcitabine, cisplatin and dexamethasone (MGDP) in patients with relapsed or refractory peripheral T cell lymphoma: A prospective, single-arm, multicenter, Phase I/II study

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial

Does intensive consolidation confer a clinical advantage over continued less intensive therapy in elderly patients with Acute Myeloid Leukemia in first remission following azacitidine plus venetoclax induction?

Safety and effectiveness of brentuximab vedotin in Chinese adult patients with classical Hodgkin's lymphoma: Results from a multicenter, prospective, observational, real-world study

Phase I study of a CD19-directed CAR-T cell therapy for Relapsed/refractory mantle cell lymphomas(MCL)

Short-term follow-up results of ultra-low-dose radiotherapy for indolent B-cell lymphoma

Genomic characterization uncovers molecular subtypes in Mantle Cell Lymphoma

Heterogeneous TP53 mutation subtypes define prognostic classification in Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only